Alleviation of the severity of SSc could be achieved by intervening in the IFIT3/TBK1 signalling pathway to inhibit the stimulation of pDCs and reduce the liberation of inflammatory factors, as illustrated in Figure 10. Here, IFIT3 is linked to systemic sclerosis.